A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-08

Study Completion Date

2023-08-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate the effect of itraconazole and carbamazepine on LY3537982 when administered as multiple doses by conducting the blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in adult healthy participants. The study will also evaluate the safety and tolerability of LY3537982. The study is conducted in two parts. Participants will stay in the research center during the study, which will last about 11 and 15 days for part 1 and part 2, respectively, not including screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3323795 in Healthy Participants

NCT02989389

Healthy

COMPLETED PHASE1

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

NCT04586920

Healthy

TERMINATED PHASE1

A Study of LY3154207 in Healthy Participants

NCT02365571

Healthy Participants

COMPLETED PHASE1

A Study of LY4005130 in Healthy Participants

NCT06690996

Healthy

ACTIVE_NOT_RECRUITING PHASE1

A Study of LY3522348 in Healthy Participants

NCT04559568

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3537982 + Itraconazole (Part 1)

LY3537982 administered orally alone followed by LY3537982 administered in combination with itraconazole orally.

Group Type EXPERIMENTAL

LY3537982

Intervention Type DRUG

Administered orally.

Itraconazole

Intervention Type DRUG

Administered orally.

LY3537982 + Carbamazepine (Part 2)

LY3537982 administered orally alone followed by LY3537982 administered in combination with carbamazepine orally.

Group Type EXPERIMENTAL

LY3537982

Intervention Type DRUG

Administered orally.

Carbamazepine

Intervention Type DRUG

Administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3537982

Administered orally.

Intervention Type DRUG

Itraconazole

Administered orally.

Intervention Type DRUG

Carbamazepine

Administered orally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Olomorasib

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
* Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive